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Abstract
Background: The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the ‘‘principal neutralizing
domain’’ of HIV-1, but has been considered too variable to serve as a neutralizing antibody (Ab) target. Structural and
immunochemical data suggest, however, that V3 contains conserved elements which explain its role in binding to virus co-
receptors despite its sequence variability. Despite this evidence of V3 conservation, the ability of anti-V3 Abs to neutralize a
significant proportion of HIV-1 isolates from different subtypes (clades) has remained controversial.
Methods: HIV-1 neutralization experiments were conducted in two independent laboratories to test human anti-V3
monoclonal Abs (mAbs) against pseudoviruses (psVs) expressing Envs of diverse HIV-1 subtypes from subjects with acute
and chronic infections. Neutralization was defined by 50% inhibitory concentrations (IC50), and was statistically assessed
based on the area under the neutralization titration curves (AUC).
Results: Using AUC analyses, statistically significant neutralization was observed by $1 anti-V3 mAbs against 56/98 (57%)
psVs expressing Envs of diverse subtypes, including subtypes A, AG, B, C and D. Even when the 10 Tier 1 psVs tested were
excluded from the analysis, significant neutralization was detected by $1 anti-V3 mAbs against 46/88 (52%) psVs from
diverse HIV-1 subtypes. Furthermore, 9/24 (37.5%) Tier 2 viruses from the clade B and C standard reference panels were
neutralized by $1 anti-V3 mAbs. Each anti-V3 mAb tested was able to neutralize 28–42% of the psVs tested. By IC50 criteria,
40/98 (41%) psVs were neutralized by $1 anti-V3 mAbs.
Conclusions: Using standard and new statistical methods of data analysis, 6/7 anti-V3 human mAbs displayed cross-clade
neutralizing activity and revealed that a significant proportion of viruses can be neutralized by anti-V3 Abs. The new
statistical method for analysis of neutralization data provides many advantages to previously used analyses.
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Introduction
Gp120, the surface subunit of the HIV-1 envelope (Env)
glycoprotein, is a critical target for antibodies (Abs) that neutralize
the virus and prevent infection (reviewed in [1]). Gp120 is bound
non-covalently to the transmembrane subunit gp41, and the two
glycoproteins are expressed on the virion surface as heterotrimers.
Gp120 serves as the virus attachment protein by binding to CD4
and the chemokine receptors CCR5 or CXCR4. Because of these
crucial functions in the virus infectious process, it is logical that
gp120 is a desired target for neutralizing Abs. However, gp120
displays astonishing agility in evading Ab neutralization
[2,3,4,5,6]. Indeed, HIV-1 gp120 is notorious for its genetic and
antigenic variability, while at the same time, its conserved regions
are poorly immunogenic and/or are not accessible on the surface
of the virion at all times [5,7,8,9,10,11,12].
Conserved Ab epitopes on gp120 have been identified based on
their recognition by broadly neutralizing human mAbs (reviewed
in [13]). Not surprisingly, these epitopes are located in the Env
regions critical for virus infectivity, which include the CD4-binding
site and the chemokine-receptor binding site which encompasses
the stem of the second variable (V2) loop, the third variable (V3)
loop, and the bridging sheet [14,15,16,17,18,19]. Recent analyses
of serum Abs from HIV-1+ subjects further confirm the
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of broadly neutralizing Abs [20,21,22,23].
The present study evaluates the breadth and potency of virus
neutralization by mAbs specific for epitopes in the V3 loop. The
V3 loop was identified in the late 1980s as the principle
neutralizing domain of HIV-1 [24], but was considered an
inappropriate target for vaccines because this region, as its name
indicates, is characterized by extreme sequence variability. This
concept was supported by early studies showing that anti-V3 Abs
raised in peptide-immunized goats and in HIV-1-infected
chimpanzees were ‘‘type-specific’’, as they were restricted in their
reactivity among a limited number of laboratory-adapted virus
strains. [25,26]. Other studies further showed that V3 epitopes
were cryptic or masked in many HIV-1 clinical isolates due to
occlusion by glycans, the V1/V2 loops, and possibly other
unidentified elements [9,27,28,29]. In contrast, however, several
studies demonstrated that mAbs and polyclonal serum Abs against
V3 can display significant degrees of cross-neutralization against
viruses within a single subtype and among multiple subtypes
[7,17,18,27,30,31,32]. Given the fact that V3 is a part of gp120
that interacts with the chemokine receptors [33,34] and that it
determines CCR5 or CXCR4 usage [35,36,37,38], V3 must
retain conserved structural elements despite its sequence variation,
and it must be exposed, at least transiently, to enable virus binding
to the chemokine receptors. These features are likely to account
for the ability of many anti-V3 Abs to recognize and neutralize
diverse HIV-1 isolates.
More recently, a variety of studies have demonstrated that V3 is
a structurally conserved domain. Thus, crystallographic and NMR
studies show conserved features of V3 when bound to several
human anti-V3 mAbs [37,39,40,41,42]. These structural studies
are consistent with the single structure available for V3 in the
context of gp120 [43], and they provide an explanation for how
anti-V3 Abs can tolerate sequence changes in their epitopes, react
immunochemically with a variety of V3 peptides and Env proteins,
and display cross-clade neutralizing activity against primary
isolates and pseudoviruses (psVs) [17,18,23,30,32,44]. Neverthe-
less, the proportion of diverse viruses which anti-V3 Abs can
neutralize and their breadth and potency against viruses from the
various HIV-1 subtypes (clades) and from patients at different
stages of infection remain controversial.
To address this issue in a comprehensive manner, HIV-1
neutralization experiments were conducted in two independent
labs to test seven anti-V3 mAbs which were selected because they
had previously been shown to display potent and cross-clade
neutralizing activity [17,18,19,45]. These mAbs were tested
against a panel of 98 pseudoviruses (psVs) expressing Envs of
HIV-1 subtypes A, AG, B, C, and D from patients with acute and
chronic HIV-1 infections. Positive neutralization was determined
for each mAb/psV pair on the basis of the commonly used cut-off
criterion, the 50% mAb inhibitory concentration (IC50). In
addition, a new statistically-based criterion was used which takes
into account (a) the area under the mAb titration curve (AUC), (b)
the slope of the titration curve, (c) the background neutralization
from irrelevant control mAbs, and (d) the background from a
control psV expressing Env from the amphotropic murine
leukemia virus (aMLV).
Materials and Methods
Ethics Statement
The study was approved by the IRB of New York University
School of Medicine. All subjects gave written informed consent.
Monoclonal antibodies
The seven human anti-V3 mAbs examined in this study were
developed using previously described cellular techniques
[17,18,19,45,46]. In brief, Epstein-Barr virus transformed periph-
eral blood mononuclear cells from HIV-1-infected subjects
producing V3-specific Abs were fused with the heteromyeloma
SHM-D33, and the resulting hybridomas were cloned to
monoclonality. Except for mAb 447-52D (designated here as
447) which was selected using a V3MN peptide, the anti-V3 mAbs
were selected using murine leukemia virus gp70-based fusion
proteins (FPs) containing V3 loops from viruses of subtypes A or B
[19,47]. These seven anti-V3 mAbs were selected from among
.50 anti-V3 mAbs generated in our lab to represent the most
potent and cross-reactive neutralizing anti-V3. Human mAbs
specific for parvovirus B19 [48] or the anthrax protective antigen
(PA) were used as negative controls. The anti-PA mAbs were
produced by cellular methods from cells derived from two different
volunteers who received an experimental vaccine consisting of
recombinant PA antigen (Gorny et al., unpublished data). All
mAbs were purified from culture supernatants by protein A or
protein G chromatography. Table 1 summarizes the properties of
the mAbs tested in this study. The 11 mAbs were sent to the
laboratories where the functional assays were performed without
any designation of their specificities.
Neutralization assay with U87 target cells
The PhenoSense
TM HIV neutralization assay was performed by
Monogram Biosciences, Inc. using the U87 target cell line
expressing CD4, CCR5, and CXCR4, as previously described
[32,49]. The U87 cell line was generated by Dr. Nathaniel Landau
(New York University School of Medicine, New York, NY). This
single round replication assay was used to test 57 psVs expressing
cloned Env gene populations extracted from viruses in patients’
plasma. The psVs were first treated with 2- or 3-fold serial
dilutions of mAbs starting from 50 mg/ml, and then incubated
with the U87 cells. After 72 hr, the levels of virus infection were
assessed by measuring luciferase activity. In this assay, the anti-
parvovirus mAb 860-55D (designated here as 860) and an aMLV
Env-expressing psV were used as negative controls, whereas psVs
expressing cloned Envs of SF162, JR-CSF, and NL4.3 were tested
as positive controls.
Neutralization assay with TZM.bl target cells
Neutralizing activities of the anti-V3 mAbs against 41 psVs
bearing single cloned Envs from neutralization-sensitive viruses
(Tier 1), from clade B and clade C primary isolates from recent
infections (Tier 2), and viruses from chronic infections were
measured using the TZM.bl cell line as target cells, as previously
described [50,51,52]. Similar to the U87 assay described above, 2-
fold serial dilutions of mAbs were prepared starting from 50 mg/ml
and used to treat psVs. The mAb/psV mixtures were then
incubated with the TZM.bl target cells, and luciferase activity
measured 48 hr later. MAbs specific for parvovirus B19 (1418 and
860) or anthrax protective antigen (3685 and 3706) were tested as
negative controls for this set of experiments.
Analyses of neutralization data
For each mAb/psV combination, a polynomial regression
(quadratic) model was used to best fit the titration curve. From
each fitted titration curve, the IC50 and area under the curve
(AUC) values were estimated to quantify neutralization potency.
The IC50 value denotes the mAb concentration that corresponds
with 50% neutralization in each fitted titration curve. AUC, on the
HIV Neutralization by V3 mAbs
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chosen concentration range divided by the concentration range.
AUC can be interpreted as the average neutralization within the
given concentration range, with 1 as the maximal value
representing 100% neutralization across the entire concentration
range specified.
To allow for comparison among different experiments and
different assays, AUC values were calculated over a fixed range of
mAb concentrations (0.39–50 mg/ml). For each mAb/psV com-
bination, we tested the none-zero null hypothesis that AUC was
less than or equal to a constant c using the Wald test. The constant
c was calculated as the mean AUC plus 2 standard deviations from
the negative controls (aMLV and/or irrelevant mAbs) achieved in
each set of experiments. The c values for the U87 and TZM.bl
experiments were 0.06 and 0.18, respectively. The one-sided Wald
test that takes into account the AUC and its variance determined
whether neutralizing activity of each test mAb/psV combination
was statistically significant at the confidence level of 0.001.
However, because the AUC values summarize the titration curves
without assuming a sigmoidal curve shape, an additional criterion
was used to ensure the detection of dose-dependent neutralization
among the titration curves with relatively low AUC values (AUC#
constant c+0.15), i.e., the presence of a positive slope between 30
and 40 mg/ml of mAb. All computations were done with free
statistical software R (http://www.r-project.org/), except for the t
test or the non-parametric one-way ANOVA test which were
performed using the GraphPad Prism 4 software to compare mean
AUC values from the designated data subsets.
Results
Comparison of AUC and IC50 values for identifying virus-
neutralizing activities of anti-V3 mAbs in the U87 assay
In the first set of experiments, six of the anti-V3 mAbs (2191,
2219, 2557, 2558, 3074, and 3869) were tested against a panel of
57 psVs prepared by Monogram Biosciences, Inc. to express Env
populations from patients’ plasma viruses when infection was due
to HIV-1 subtypes A, B, C, or D; anti-V3 mAb 447 was tested
against a subset of 26 psVs from this same panel. The panel of 57
psVs was chosen at Monogram to represent Envs from different
subtypes, from subjects in different geographic areas, infected by
different routes and at different stages of infection, i.e., from
acutely-infected and chronically-infected subjects with different
profiles of disease progression (rapid progressors and long-term
non-progressors). In addition to the 57 psVs, four psVs prepared
from single cloned Envs of SF162, JR-CSF, NL4.3, and aMLV
were tested as positive and negative controls. The target cell line
used in this set of experiments was CD4+CCR5+CXCR4+ U87.
To determine the neutralization in each mAb/psV combina-
tion, both the AUC and IC50 values were calculated from each
neutralization titration curve. Figure 1 shows neutralization curves
for mAb 2191 against nine representative psVs, including the
negative psV control aMLV and the positive control SF162 psV;
the corresponding AUC and IC50 values are also shown. Based on
the statistical analyses of the AUC values described in the
Materials and Methods, the neutralization curves for mAb 2191
against psVs SF162, Acute-B-011, Chronic-B-034, Chronic-B-
029, A-015, and Acute-B-016 are classified as positive (i.e.,
significant neutralization, p,0.001), while the neutralization
curves against psVs C-026, D-030, and aMLV are negative (i.e.,
neutralization is not significant).
It is noteworthy that neutralization by mAb 2191 of psVs
Chronic B-034, A-015, and Acute-B-016 is considered statistically
significant by the AUC analysis despite the fact that 50%
neutralization was not achieved with the highest mAb concentra-
tion (50 mg/ml). For example, 50 mg/ml of mAb 2191 neutralized
A-015 to a level of 36%; nonetheless, the neutralization curve
shows a positive dose-response relationship and was clearly
distinguishable from the data generated with mAb 2191 vs. the
negative control psV, aMLV, and from the data generated vs. psV
D-030 which essentially overlay those of the aMLV negative
control. Thus, while the neutralizing activity of mAb 2191 against
these three psVs reached a maximum of only 36% at 50 mg/ml,
significant neutralizing activity was identified by statistical analysis
(p,0.001).
Neutralization plots are shown in Figure 2 for seven anti-V3
mAbs and one control mAb, 860, against seven representative
psVs carrying Envs from different HIV-1 subtypes, a positive
control psV (SF162), and a negative psV control (aMLV). Dose-
dependent neutralization was observed against a significant
proportion of the psVs with each anti-V3 mAb; none of the psVs
were neutralized by the control anti-parvovirus mAb 860. One
Table 1. Characteristics of human mAbs used for this study.
mAbs Specificity Isotype Subtype of the infecting virus Country of origin Reference
2191 V3 IgG1 l B USA [19]
2219 V3 IgG1 l B USA [19]
2557 V3 IgG1 l CRF02_AG Cameroon [18]
2558 V3 IgG1 l CRF02_AG Cameroon [18]
3074 V3 IgG1 l CRF02_AG Cameroon [18]
3869 V3 IgG1 l nd Cameroon [46]
447 V3 IgG3 l B USA [17,45]
860 parvovirus IgG1 l - USA [48]
1418 parvovirus IgG1 k - USA [48]
3685 Anthrax, PA IgG1 l - USA 1
3706 Anthrax, PA IgG1 l - USA 1
nd – not determined.
PA – protective antigen of anthrax.
1– Gorny et al., unpublished data.
doi:10.1371/journal.pone.0010254.t001
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V3 mAbs against the positive control SF162 psV. While several
mAb/psV combinations achieved .50% neutralization at the
highest mAb concentration tested (50 mg/ml), for many combina-
tions, 50% neutralization was not attained at this concentration
even though dose-response relationships were displayed by the
neutralization curves which were clearly above background (see
below).
When IC50valueswerecalculatedforall mAb/psV combinations
tested in the U87 assay system (Figure 3), 18 of the 57 (32%) psVs
were neutralized by one or more anti-V3 mAbs at #50 mg/ml, with
IC50 values ranging from 2.65 to 42.73 mg/ml. Statistical analysis
was then performed using the AUC method described above.
Figure 4 shows the same neutralization matrix as that shown in
Figure 3 but with AUC values. The AUC values of all mAb/psV
combinations tested, including the negative and positive controls,
ranged from 20.17 to 1.00. Significant neutralization was observed
against 33 out of 57 (58%) psVs by $1 anti-V3 mAbs. Note that
significant neutralization was not determined by a particular cut-off
value, but rather by the Wald test and the slope criteria described in
theMaterialsand Methodssection.Therefore,neutralization curves
with the same AUC values may not be equally significant due to
differences in the slopes and the variance of the fitted curves.
Thus, use of the AUC-based statistical analysis resulted in the
detection of nearly twice as much neutralizing activity in this panel
as did analysis by IC50. The difference was primarily due to low
level neutralizing activity. For example, no neutralization was
detected against clade A psV MGRM-A-015 by any of the seven
mAbs when measured by IC50 (Figure 3), but 6 of 7 mAbs showed
significant neutralization of this psV by the AUC analysis
(p,0.001; Figure 4).
Neutralizing activities of anti-V3 mAbs against multiple
HIV-1 subtypes are detected in the U87 assay
The neutralizing activities of the seven mAbs were observed
across psVs carrying the Envs of the four subtypes tested in the
U87 assay. Twenty-one of the 27 (78%) psVs with subtype B Envs
from acute and chronic infections and 8 of the 10 (80%) psVs with
subtype C Envs were neutralized by at least one anti-V3 mAb
(Figure 4). In contrast, subtypes D and A psVs were less sensitive to
neutralization, with only one (10%) and three (30%) of these psVs
sensitive to the anti-V3 mAbs, respectively.
The median IC50 value for anti-V3/psV pairs with an
IC50,50 mg/ml in this set of experiments was 18.65 mg/ml
(Figure 3), and the median AUC value for anti-V3/psV pairs with
significant neutralization was 0.24. This AUC value was essentially
identical to the median AUC for the anti-V3 mAbs that
neutralized JR-CSF (median AUC=0.26). As expected, this value
is lower than that obtained for psVs SF162 and NL43 (median
AUCs=1.00 and 0.76, respectively); these psVs are known to be
highly sensitive to neutralization. Notably, the median AUC values
of mAbs that significantly neutralized subtype B and subtype C
psVs (0.25 and 0.21, respectively) were comparable, indicating
that the anti-V3 mAbs neutralize subtypes B and C viruses with
similar potencies. It is also noteworthy that none of the mAbs
tested were derived from subtype C-infected patients, yet they
effectively neutralized 8 of the 10 clade C psVs.
Neutralizing activities of anti-V3 mAbs against multiple
HIV-1 subtypes are also detected in the TZM.bl assay
In a second set of experiments, the same anti-V3 mAbs were
tested for their ability to block infection of TZM.bl cells by 41
psVs carrying single cloned HIV-1 Envs, including ten Tier 1
Envs (subtypes A, AG, B and C), 12 Tier 2 subtype B Envs, and
12 Tier 2 subtype C Envs. The Tier 1 and Tier 2 Envs have been
selected for use in standard psV panels of neutralization assays.
The Tier 2 Envs were cloned out of primary HIV-1 isolates from
acute and early infection and were moderately resistant to
polyclonal and monoclonal Ab reagents, while the Tier 1 Envs
were highly sensitive to neutralization [50,51]. In addition, psVs
were tested carrying cloned Envs from seven clade B viruses
isolated from chronically-infected individuals. As negative
Figure 1. The neutralization of nine HIV-1 pseudoviruses by mAb 2191 using U87 as target cells. The neutralization curves of anti-V3
mAb 2191 against nine selected HIV-1 pseudoviruses are shown with their corresponding AUC and IC50 values. Fifty percent neutralization is denoted
by the dashed line. Significant neutralization at the confidence level of p,0.001 (denoted with * after AUC values) was determined statistically based
on comparison with the AUC values of the negative controls together with the slopes of the titration curves as described in Materials and Methods.
For viruses coming from patients where the date of infection is known, viruses are denoted as coming from acutely- or chronically-infected patients,
and the clade of the virus is denoted by the capital letter in its name (A, B, C or D).
doi:10.1371/journal.pone.0010254.g001
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(860, 1418, 3685, and 3706) were used to establish background
levels of neutralization.
The curves depicting the neutralizing activities of the seven anti-
V3 mAbs and the negative control mAb 1418 against nine of the
41 psVs are shown in Figure 5. Generally higher levels of
neutralization were detected in the TZM.bl assay than in the U87
assay described above. For example, in the TZM.bl assay, but not
the U87 assay, neutralization levels .80% were frequently
observed. However, the background values from the negative
control mAbs were also higher in the TZM.bl assay than those
generated in the U87-based experiments (Figure 5 vs. Figure 2).
Comparably high background levels of neutralization were also
observed with the other three negative control mAbs tested in the
TZM.bl assay (data not shown). One should note, however, that
the high background levels observed in the TZM.bl assay might be
attributable to the particular psVs tested in the panel and not only
to the assay or target cells. For instance, background neutralization
of .20% was consistently observed with psVs ZM214M.PL15 and
HXB2, but not with psVs MW965.26, 242-14, and H035.18
(Figure 5).
When 50% neutralization was used as a cut-off for positive
neutralization with the TZM.bl experimental data, 22 of 41 (54%)
psVs were neutralized, with IC50 values for neutralizing mAbs
ranging from ,0.39 to 48.54 mg/ml (Figure 6). The median IC50
value for all mAb/psV combinations with IC50 of ,50 mg/ml was
1.91 mg/ml. When calculated for the 31 Tier 2 and chronic psVs
(i.e., excluding the data from Tier 1 psVs), the median IC50 was
23.77 mg/ml. When assessed by AUC (Figure 7), the results were
similar: 23 of 41 (56%) psVs were neutralized, with significant
AUC values ranging from 0.23 to 1.00. No significant neutrali-
zation was measured using either IC50 or AUC with any of the
four negative control mAbs (Figures 6 and 7, and data not shown).
Using the AUC analysis, the Tier 1, Tier 2, and chronic viruses
showed different patterns of neutralization by the anti-V3 mAbs in
the TZM.bl assay. All 10 of 10 Tier 1 psVs with Envs from
subtypes A, AG, B and C were neutralized by $1 anti-V3 mAbs
(Figure 7). Indeed, a single anti-V3 mAb (3074) was able to
neutralize all of the 10 Tier 1 psVs, while each of the remaining six
anti-V3 mAbs neutralized 5 to 9 of the 10 Tier 1 psVs. The AUC
values achieved against the Tier 1 psVs were high, with a median
of 0.78 (range 0.24 to 1.00) for all positive mAb/psV combina-
Figure 2. Neutralization curves of anti-V3 mAbs against representative HIV-1 psVs tested using the U87 target cell. Seven anti-V3
mAbs (2191, 2219, 2557, 2558, 3074, 3869, and 447) were tested for neutralization against HIV-1 pseudoviruses using the U87 cell line as target cells.
MAb 860, specific for parvovirus, and a pseudovirus expressing the aMLV Env were used as negative controls in this assay. The titration curves from
eight selected psVs and the aMLV psV control are shown. Curve fitting was performed using the polynomial regression (quadratic) model described
in Materials and Methods. Fifty percent neutralization is denoted by the dashed line. Virus nomenclature is denoted as described in Figure 1.
doi:10.1371/journal.pone.0010254.g002
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AUC values of 0.90 to 1.00.
One or more anti-V3 mAbs were also able to neutralize six of
12 (50%) clade B Tier 2 psVs, with a median AUC value of 0.35
(range 0.23–0.91) for all the positive mAb/psV combinations.
These data parallel those shown above (Figure 4) in which anti-V3
mAbs neutralized 12 of the 17 (71%) subtype B psVs with Envs
derived from acutely-infected patients tested in the U87 assay, a
group of psVs that meet the criteria for Tier 2 viruses. Among the
seven chronic subtype B psVs tested in the TZM.bl assay, four
(57%) were also neutralized by $1 anti-V3 mAbs (median
AUC=0.37, range 0.24–0.67) (Figure 7). In comparison, 90% of
psVs with subtype B Envs from chronically-infected progressors
and long-term non-progressors tested in the U87 assay were
neutralized by anti-V3 mAbs (Figure 4). The results in the two
assays show qualitatively that anti-V3 mAbs can neutralize Tier 2
psVs from clade B as well as psVs derived from the viruses of
chronically-infected individuals. The quantitative differences
between the two assays may be attributable to the particular
panel of psVs tested.
Among 12 psVs with clade C Tier 2 subtype C Envs, statistically
significant neutralization was achieved against three
(ZM233M.PB6, ZM109F.PB4, and CAP210.2.00E8) in the
TZM.bl assay. The neutralization of ZM233M.PB6 and
ZM109F.PB4 was mediated by three and four anti-V3 mAbs,
respectively, while CAP201.2.00E8 was neutralized by only one
(mAb 3074) (Figure 7). In contrast, 8 of 10 (80%) subtype C psVs
were neutralized by these same anti-V3 mAbs in the U87
experimental set (Figure 4). Here the comparison is not as direct,
since the clade C Tier 2 panel used in the TZM.bl assay was
derived from individuals recently infected with subtype C viruses,
whereas the Envs of clade C psVs tested in the U87 experiments
came from individuals whose date of infection was not known, but
were likely to be in the chronic stage of infection.
Combined data from the U87 and TZM.bl experiments
demonstrate broad neutralizing activities of anti-V3
mAbs across Envs from different subtypes and from
different stages of infection
By applying the same AUC-based statistical analyses to the two
independent experiments, we observed that, 56 of 98 (57%) psVs
tested were neutralized significantly by $1 anti-V3 mAbs
(Table 2). These 56 sensitive psVs expressed Envs of diverse
subtypes, including subtypes A, AG, B, C and D. Even when the
10 Tier 1 psVs were excluded from the combined data, significant
neutralization was detected by $1 anti-V3 mAbs against 46 of 88
(52%) psVs from subtypes A, B, C and D. Furthermore, 9 of 24
(37.5%) Tier 2 viruses from the clade B and C standard panels
were neutralized by $1 anti-V3 mAbs. Hence, the ability of anti-
V3 mAbs to neutralize across different subtypes is observed
consistently in both U87 and TZM.bl experiments. This
establishes the ability of many anti-V3 mAbs to display cross-
clade neutralizing activity and demonstrates conclusively that anti-
V3 Abs can be broad in their reactivity and are not exclusively
type- or clade-specific.
Subtype B psVs with Envs from viruses derived from
chronically- and acutely-infected subjects were compared for
neutralization sensitivity by anti-V3 mAbs. The data from both
U87 and TZM.bl experimental sets consistently show that anti-V3
mAbs were effective against significant fractions of psVs with Envs
from either chronic or acute infections. In the U87 experiments,
90% (9/10) and 71% (12/17) of psVs with Envs from chronic and
acute infections, respectively, were neutralized by $1 anti-V3
mAbs (Figure 4 and Table 2). The mAbs showed a trend toward
better potency against psVs with chronic Envs (AUC=0.12 to
0.54; median =0.30) than against acute Envs (AUC=0.10 to
0.46; median =0.23); this difference did not reach statistical
significance. In the TZM.bl experiments, psVs with subtype B
Envs from both chronic (4/7 [57%]) and acute (Tier 2; 6/12
[50%]) infections were also sensitive to neutralization by anti-V3
mAbs (Figure 7 and Table 2), and there was essentially no
difference in the potency of the mAbs against viruses with chronic
Envs (AUC=0.24–0.67, median =0.37) vs. those with acute Envs
(Tier 2; AUC=0.23–0.91, median =0.35).
Different anti-V3 mAbs display unique patterns of
neutralization
Each anti-V3 mAb tested was able to neutralize 28–42% of the
98 psVs tested, whereas the four anti-parvovirus and -anthrax
mAbs used as negative controls did not neutralize any of the psVs.
However, the data in Figures 4 and 7 clearly show that each anti-
V3 mAb displays a unique pattern of psV neutralization. To
illustrate these distinct patterns of neutralization, data from three
mAbs, 2191, 3074, and 447, are described in detail this section.
Based on statistical analyses of the AUC data, mAb 2191 was
found to neutralize the highest proportions of psVs, and this was
consistently observed in both the U87 and TZM.bl assays
(Figures 4 and 7). Twenty-four of 57 (42%) and 17 of 41 (41%)
psVs in the respective panels were significantly neutralized by
mAb 2191. Importantly, this single mAb displays neutralizing
activity across multiple subtypes, including psVs carrying Envs
from Tier 1, Tier 2, acute and chronic viruses from subtype B,
from Tier 2 and chronic viruses from subtype C, from chronic
clade A and D viruses, and from Tier 1 AG viruses. The frequency
of subtype B psVs neutralized by mAb 2191 (which was derived
from a clade B-infected individual) was greater than that for the
non-B psVs, and the potency against the subtype B psVs was also
notably stronger. This inter-subtype neutralizing activity was not
unique to mAb 2191. The other five anti-V3 mAbs (2219, 2557,
2558, 3074, and 3869) were also effective against psVs expressing
different Env subtypes, as they each neutralized 28–36% of the 98
psVs tested at levels that were statistically significant. These data
demonstrate that a single anti-V3 mAb has the capacity to mediate
neutralization against HIV-1 of diverse subtypes.
Previous studies have shown that anti-V3 mAbs derived from
African donors infected with HIV-1 isolates of non-B subtypes
show different patterns of psV neutralization than those derived
from subtypes B-infected subjects, and that the non-B derived
mAbs have a tendency to exhibit broader and more potent
neutralization against non-B viruses [18]. Of the four non-B
derived mAbs studied here, mAbs 3074 and 3869 exhibited
remarkable neutralization patterns: these two mAbs neutralized
eight of the 10 subtype C psVs in the U87 experiments (Figure 4).
MAb 3074, for example, which was derived from a clade AG-
Figure 3. The IC50 values of anti-V3 mAbs against 57 HIV-1 pseudoviruses tested using the U87 target cell line. The IC50 values were
estimated from the titration curves of all mAb/psV combinations and are highlighted according to the color-coded scale. Pseudoviruses expressing
Envs of JRCSF, NL3.4, and SF162 were tested as positive controls, whereas the irrelevant anti-parvovirus mAb 860 and aMLV Env-expressing psV were
used as negative controls. When 50% neutralization was not achieved at the highest mAb concentration tested (50 mg/ml), the IC50 values are shown
as .50.
doi:10.1371/journal.pone.0010254.g003
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of 10 clade C psVs with AUC values ranging from 0.17 to 0.46
(Figure 4); when 50% neutralization was achieved, IC50 values
ranged between 8.51 and 24.20 mg/ml (Figure 3). This mAb also
neutralized two clade C Tier 2 psVs tested in the TZM.bl
experiments, with AUC values of 0.27 and 0.34 (Figure 7). Using
the IC50 criterion, three clade C Tier 2 viruses were neutralized,
with IC50 values of 7.33 to 41.48 mg/ml (Figure 6). In contrast, the
neutralization of mAb 3074 against acute, chronic, and Tier 2
subtype B psVs was more sporadic and less potent. These data
provide clear evidence for the distinct and complementary
specificities of neutralizing activities mediated by the individual
anti-V3 mAbs and suggest that increased breadth of virus
neutralization can be attained by combinations of selected anti-
V3 mAbs.
In contrast to the six anti-V3 mAbs described above, the
anti-V3 mAb 447, which has, until now, been considered as
the prototypic anti-V3 mAb, displays more limited breadth of
neutralization across subtypes. Although mAb 447 significantly
neutralized 27/65 (42%) psVs in the U87 and TZM.bl
experiments, it was effective mainly against psVs with subtype
Ba n dT i e r1E n v s( F i g u r e s4a n d7 ) .T h i si ss t r i k i n g l ys i m i l a rt o
the data published previously showing that mAb 447
neutralized 38% and 45% of various clade B psVs panels but
a very small proportion of psVs from other subtypes [30,31],
The data suggest that mAb 447 tends to be a ‘‘clade B-
specific’’ anti-V3 mAb, and is clearly distinct from the other
much more broadly reactive anti-V3 mAbs tested in these
studies. This finding is consistent with previously published
data showing that the V3 motif critical for mAb 447
Figure 4. The AUC values of anti-V3 mAbs against 57 HIV-1 pseudoviruses tested using the U87 target cell line. AUC values were
estimated from the titration curves as described in the Materials and Methods section. Statistically significant neutralization at p,0.001 is color-coded
according to the designated scale.
doi:10.1371/journal.pone.0010254.g004
Figure 5. Neutralization curves of anti-V3 mAbs against representative HIV-1 psVs tested using the TZM.bl target cell line.
Seven anti-V3 mAbs were tested against HIV-1 psVs in the TZM.bl experiment. The titration curves observed against nine selected viruses are
shown. The background neutralization observed with the irrelevant control mAb 860 is also shown for comparison. Curve fitting was performed
using the polynomial regression (quadratic) model described in Materials and Methods. Fifty percent neutralization is denoted by the dashed
line.
doi:10.1371/journal.pone.0010254.g005
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315 (R) at the GPGR arch of
the V3 crown [40,44,53] and that this motif is generally
restricted to subtype B viruses, whereas the typical sequence at
the V3 arch of the other subtypes is GPGQ.
Discussion
By testing seven different anti-V3 mAbs against 98 psVs with
either single cloned Envs or cloned Env populations in two
Figure 6. The IC50 values of anti-V3 mAbs against 41 HIV-1 pseudoviruses tested using the U87 target cell line. The IC50 values were
estimated from the titration curves of all mAb/psV combinations and are shown with the color-coded scale. When 50% neutralization was not
achieved at the highest mAb concentration tested (50 mg/ml), the IC50 values are shown as .50. Four different irrelevant mAbs (860, 1418, 3685, and
3706) were used as negative controls in this experiment with comparable results, but only the mAb 860 data are shown.
doi:10.1371/journal.pone.0010254.g006
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different target cells, this study has demonstrated the ability of
human anti-V3 mAbs to neutralize diverse HIV-1 strains from
multiple subtypes derived from patients at different stages of
infection. Overall, the data show that 57% of the 98 psVs tested
were sensitive to neutralization by one or more of the seven anti-
Figure 7. The AUC values of anti-V3 mAbs against 41 HIV-1 pseudoviruses tested using the TZM.bl target cell line. The AUC values
were calculated from the titration curves as described in the Materials and Methods section. All mAb/psV pairs with statistically significant
neutralization at p,0.001 are color-coded according to the designated scale. The irrelevant anti-parvovirus mAb 1418 was used together with three
other control mAbs (data not shown) as negative controls.
doi:10.1371/journal.pone.0010254.g007
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28–42% of these psVs. Given the reactivity of these monoclonal
reagents, the data suggest that polyclonal anti-V3 Ab responses
will neutralize an even greater proportion of HIV-1 isolates than
any single anti-V3 mAb or cocktail of anti-V3 mAbs. Indeed, this
hypothesis is corroborated by recent findings showing that sera
from rabbits that were primed with gp120 DNA and boosted with
a V3-fusion protein exhibited a greater breadth of neutralizing
activity than pools of anti-V3 mAbs [32]. The accumulated data
on the breadth of the neutralizing activity of anti-V3 mAbs, from
immune sera induced with a vaccine focusing the Ab response on
V3 and from polyclonal serum anti-V3 Abs from infected
individuals [54] suggest that V3 is one of the Env epitopes of
HIV-1 that should be targeted by vaccines.
The extent of cross-reactivity displayed by the anti-V3 mAbs is
not surprising in light of the structural and bioinformatics data
published in recent years which show the presence of several
conserved structural elements in the V3 loop. Huang et al. [43]
demonstrated three regions of the V3 loop: a base which is
attached to the gp120 core, a flexible stem, and a crown, consisting
of ,14 amino acids at the center of the loop which contains all
epitopes recognized by anti-V3 mAbs [40,41,42,44,55,56,57].
One of the conserved features of the V3 crown is the presence of
the GPG motif at the tip of the loop that propels the distal tip of
the V3 crown to adopt a unique b-hairpin structure. MAb 447, for
example, interacts with this conserved GPG turn via hydrophobic
interactions, and with the main chain of the N-terminal V3 b-
strand flanking the GPG turn, rendering this mAb unaffected by
side-chain differences in the highly variable V3 N-terminal b-
strand [40,42,53]. These studies also reveal that the reactivity of
mAb 447 is restricted by a polar interaction with the side chain of
the R residue in the GPGR motif found mainly among viruses
of subtype B but infrequently in other subtypes.
From the crystal structures of V3 peptides bound by different
mAbs, additional conserved elements in the V3 epitopes have been
identified that provide the structural basis for anti-V3 cross-
reactivity. The cross-reactivity of mAb 2219, for example, is due to
its ability to recognize conserved residues on the hydrophobic face
of V3, composed of residues flanking the GPG tip [41], and
further studies indicate that the 2219 epitope occurs in 30% of
worldwide isolates [53]. Additional data based on viral bioinfor-
matics and modeling studies demonstrate that the variability in V3
is, in fact, restricted to a small zone on the surface of the
hydrophilic face of the V3 loop b-hairpin [58]. Thus, there is
considerable structural conservation of V3, which is consistent
with the requirement for V3 to participate in coreceptor binding
regardless of the amino acid sequence variability this region
displays.
It is noteworthy that the breadth attained by individual anti-V3
mAbs assessed by IC50 values, i.e., 28% to 42% against 98 psVs, is
not dissimilar to that of other broadly neutralizing mAbs such as
b12 and 2G12 which, respectively, neutralized 35% and 32% of
162 viruses tested in the same U87 assay and assessed by the same
criterion [15]. It is also comparable with the breadth of
neutralization recently reported for mAb HGN194, which
recognizes a conserved epitope in the V3 crown [59]. The anti-
MPER mAbs 2F5 and 4E10 show broader activity (60% and 98%,
respectively), as do the newly isolated mAbs PG9 (79%) and PG16
(73%) that recognize quaternary neutralizing epitopes composed
of portions of the V2 and V3 loops on HIV-1 virions. As noted
above, however, the polyclonal response to a neutralizing domain
such as V3 or the CD4 binding site may have much greater
breadth than that displayed by any single mAb, or indeed, by a
cocktail of mAbs.
The issue of the concentration of individual mAbs and
polyclonal Abs needed for protection in vivo has received much
attention, and the consensus has undergone vast changes as new
data have emerged. Whereas early passive immunization exper-
iments with mAbs suggested that extremely high levels of serum
Ab concentrations were needed for protection [60,61], recent data
from a SHIV/macaque model suggest that as little as 30–60 mg/
ml of an effective mAb may be sufficient to protect against a low
dose challenge, comparable to that occurring in nature [62]. Thus,
the levels of potency offered by the various broadly neutralizing
anti-gp41 and gp120 mAbs, including those specific for V3, may
well offer the requisite protection given their median in vitro IC50
values of ,30 mg/ml (see Results and [15]).
In addition to providing data documenting the breadth and
potency of anti-V3 mAbs, this study demonstrates the utility of a
new method for objective statistical analysis of neutralization data.
In the past, low levels of Ab-mediated neutralization have been
essentially overlooked, as neutralizing activities have convention-
ally been presented as the titers or Ab concentrations required to
reach various arbitrary neutralization levels; indeed, inhibitory Ab
Table 2. Summary of data on psV neutralization by anti V3 mAbs.
Env subtype Category or stage of infection No. psVs neutralized* Total psVs tested % neutralized Assay
All 56 98 57% U87 & TZM.bl
All except Tier 1 46 88 52% U87 & TZM.bl
A, AG, B & C Tier 1 10 10 100% TZM.bl
B & C Tier 2 9 24 38% TZM.bl
B Acute 12 17 71% U87
B Tier 2 6 12 50% TZM.bl
B Chronic (Progressor & LTNP) 9 10 90% U87
B Chronic 4 7 57% TZM.bl
A unknown 3 10 30% U87
C Tier 2 3 12 25% TZM.bl
C unknown 8 10 80% U87
D unknown 1 10 10% U87
*Positive neutralization defined by p,0.001 in AUC analysis with $1 anti-V3 mAb(s).
doi:10.1371/journal.pone.0010254.t002
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various HIV studies. If background levels for negative controls
approach 50% neutralization, as in the case of the TZM.bl assay
(see the Figure 5 panel showing data from assays with the negative
control mAb 1418), then using IC50 values approximate statistical
significance and little neutralizing activity is missed. This agrees
with a recent report demonstrating a high correlation of IC50 titers
with partial AUC values (defined as the areas of the titration
curves measured between 20 and 100% neutralization) for a large
panel of psVs tested using TZM.bl target cells [63]. Thus, in the
data from the TZM.bl assay, the IC50 values and AUC analysis
show, respectively, 54% and 56% of psVs neutralized by one or
more anti-V3 mAbs. However, if, as in the case of the U87 assay,
background levels rarely exceed 20% neutralization (see the
Figure 2 panel showing data from assays with the negative control
mAb 860), then using IC50 values censor all of the data between
background and 50%, resulting in an underestimate of neutral-
izing activity. In this latter case, the use of AUC more
comprehensively assesses neutralizing activity. In the data from
the U87 assay, the proportions of psVs neutralized are 32% and
58% when analyzed by IC50 and AUC, respectively. Thus, one
advantage of using the AUC method is its ability to detect low
levels of neutralizing activity that might otherwise be missed and
might be biologically relevant.
There are several additional advantages to the AUC analysis of
neutralization data. 1) It allows statistically-based assessment of all
neutralization data, with no preconceived cut-off points. This
method takes into account the entire data from each titration
curve, the background neutralization for a given assay, and the
slope of the curve. It then utilizes a statistical test to determine
significant activity. 2) The AUC summarizes neutralization
responses across a range of Ab concentrations without requiring
assumptions about the sigmoidal shape of the titration curve.
Indeed, the majority of neutralization curves are not sigmoidal
(Figures 1, 2, and 5). 3) AUC does not rely on a single point in
various neutralization curves which may or may not be in the
linear portion of each of the curves. 4) All data are used, and none
are censored, Thus, Abs that do not attain the selected level of
neutralization at the highest concentration tested (e.g. 50 mg/ml)
are not ‘‘censored’’, i.e., listed as ‘‘,50’’. And, 5) a uniform, AUC-
based statistical test can be applied for analysis and comparison of
multiple data sets from independent experiments. This approach
may therefore prove useful for analyses of neutralization data from
preclinical and clinical trials that evaluate incremental improve-
ments in the designs of candidate HIV/AIDS vaccines as they are
being optimized.
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